Decreased PTH levels accompanied by low bone formation are associated with vertebral fractures in postmenopausal women with type 2 diabetes

Journal of Clinical Endocrinology and Metabolism

Volumn 97, Issue 4, 2012, Pages 1277-1284

  Yamamoto, Masahiro ^a   Yamaguchi, Toru ^a   Nawata, Kiyoko ^b   Yamauchi, Mika ^a   Sugimoto, Toshitsugu ^a  

^a SHIMANE UNIVERSITY FACULTY OF MEDICINE   (Japan)

^b SHIMANE UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; CREATININE; HEMOGLOBIN A1C; INSULIN; METFORMIN; OSTEOCALCIN; PARATHYROID HORMONE; PHOSPHATE; PIOGLITAZONE; SULFONYLUREA;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BONE DENSITY; BONE TURNOVER; CALCIUM BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; POSTMENOPAUSE; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; VERTEBRA FRACTURE; VITAMIN BLOOD LEVEL;

AGED; AGED, 80 AND OVER; AGING; BIOLOGICAL MARKERS; BONE REMODELING; BONE RESORPTION; CROSS-SECTIONAL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HOSPITALS, UNIVERSITY; HUMANS; JAPAN; MALE; MIDDLE AGED; OSTEOCALCIN; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; PARATHYROID HORMONE; RISK; SEX CHARACTERISTICS; SPINAL FRACTURES;

EID: 84859537772     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-2537     Document Type: Article

References (26)

1. Vestergaard P 2007 Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes - a meta-analysis. Osteoporos Int 18:427-444 (Pubitemid 46354916)
2. Janghorbani M, VanDam RM, Willett WC, Hu FB 2007 Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495-505 (Pubitemid 47283633)
3. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T 2009 Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res 24:702-709
4. Anonymous 2001 Osteoporosis prevention, diagnosis, and therapy. JAMA 285:785-795
5. Cakatay U, Telci A, Kayali R, Akçay T, Sivas A, Aral F 1998 Changes in bone turnover on deoxypyridinoline levels in diabetic patients. Diabetes Res Clin Pract 40:75-79 (Pubitemid 28308397)
6. Pedrazzoni M, Ciotti G, Pioli G, Girasole G, Davoli L, Palummeri E, Passeri M 1989 Osteocalcin levels in diabetic subjects. Calcif Tissue Int 45:331-336 (Pubitemid 20028359)
7. Gerdhem P, Isaksson A, Akesson K, Obrant KJ 2005 Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 16:1506-1512 (Pubitemid 41790853)
8. Inaba M, Nagasue K, Okuno S, Ueda M, Kumeda Y, Imanishi Y, Shoji T, Ishimura E, Ohta T, Nakatani T, Kim M, Nishizawa Y 2002 Impaired secretion of parathyroid hormone, but not refractoriness of osteoblast, is a major mechanism of low bone turnover in hemodialyzed patients with diabetes mellitus. Am J Kidney Dis 39:1261-1269 (Pubitemid 34591944)
9. Inaba M, Okuno S, Kumeda Y, Yamakawa T, Ishimura E, Nishizawa Y 2005 Increased incidence of vertebral fracture in older female hemodialyzed patients with type 2 diabetes mellitus. Calcif Tissue Int 76:256-260 (Pubitemid 40991396)
10. Dobnig H, Piswanger-Sölkner JC, Roth M, Obermayer-Pietsch B, Tiran A, Strele A, Maier E, Maritschnegg P, Sieberer C, Fahrleitner-Pammer A 2006 Type 2 diabetes mellitus in nursing home patients: effects on bone turnover, bone mass, and fracture risk. J Clin Endocrinol Metab 91:3355-3363 (Pubitemid 44402104)
11. Schmidt-Gayk H, Spanuth E, Kötting J, Bartl R, Felsenberg D, Pfeilschifter J, Raue F, Roth HJ 2004 Performance evaluation of automated assays for β-CrossLaps, N-MID-osteocalcin and intact parathyroid hormone (BIOROSE Multicenter Study). Clin Chem Lab Med 42:90-95 (Pubitemid 38401475)
12. Garnero P, Vergnaud P, Hoyle N 2008 Evaluation of a fully automated serum assay for total N-terminal propeptide of type I collagen in postmenopausal osteoporosis. Clin Chem 54:188-196 (Pubitemid 351182613)
13. Genant HK, Wu CY, van Kuijk C, Nevitt MC 1993 Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 8:1137-1148 (Pubitemid 23261108)
14. Atsumi K, Kushida K, Yamazaki K, Shimizu S, Ohmura A, Inoue T 1999 Risk factors for vertebral fractures in renal osteodystrophy. Am J Kidney Dis 33:287-293 (Pubitemid 29072230)
15. Okazaki R, Totsuka Y, Hamano K, Ajima M, Miura M, Hirota Y, Hata K, Fukumoto S, Matsumoto T 1997 Metabolic improvement of poorly controlled noninsulin-dependent diabetes mellitus decreases bone turnover. J Clin Endocrinol Metab 82:2915-2920 (Pubitemid 27385648)
16. Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Kurioka S, Yano S, Sugimoto T 2009 Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in type 2 diabetes mellitus. J Clin Endocrinol Metab 94:45-49
17. Rubin MR, Dempster DW, Zhou H, Shane E, Nickolas T, Sliney Jr J, Silverberg SJ, Bilezikian JP 2008 Dynamic and structural properties of the skeleton in hypoparathyroidism. J Bone Miner Res 23:2018-2024
18. Danese MD, Kim J, Doan QV, Dylan M, Griffiths R, Chertow GM 2006 PTH and the risks for hip, vertebral, and pelvic fractures among patients on dialysis. Am J Kidney Dis 47:149-156 (Pubitemid 41828277)
19. Heaney RP 2003 Is the paradigm shifting? Bone 33:457-465 (Pubitemid 37222371)
20. Mashiba T, Hirano T, Turner CH, Forwood MR, Johnston CC, Burr DB 2000 Suppressed bone turnover by bisphosphonates increases microdamage accumulation and reduces some biomechanical properties in dog rib. J Bone Miner Res 15:613-620 (Pubitemid 30174014)
21. Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E 1990 Effects of high concentrations of glucose on PTH secretion in parathyroid cells. Kidney Int 37:1522-1527 (Pubitemid 20198035)
22. Brownlee M 1995 Advanced protein glycosylation in diabetes and aging. Annu Rev Med 46:223-234
23. Yamamoto T, Ozono K, Miyauchi A, Kasayama S, Kojima Y, Shima M, Okada S 2001 Role of advanced glycation end products in a dynamic bone disease in patients with diabetic nephropathy. Am J Kidney Dis 38:S161-S164 (Pubitemid 32927634)
24. Yamamoto M, Yamaguchi T, Yamauchi M, Yano S, Sugimoto T 2008 Serum pentosidine levels are positively associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes. J Clin Endocrinol Metab 93:1013-1019 (Pubitemid 351398587)
25. Yamamoto M, Yamaguchi T, Yamauchi M, Sugimoto T 2009 Low serum level of the endogenous secretory receptor for advanced glycation end products (esRAGE) is a risk factor for prevalent vertebral fractures independent of bone mineral density in patients with type 2 diabetes. Diabetes Care 32:2263-2268
26. Chaudhary DP, Sharma R, Bansal DD 2010 Implications of magnesium deficiency in type 2 diabetes: a review. Biol Trace Elem Res 134:119-129